

a³ 7. (Amended) A dosage form according to [any preceding] Claim 1 in which the total volume of treatment fluid does not exceed 10 μl .

a⁴ 9. (Amended) A method of ophthalmic treatment comprising delivering to an eye a dosage form according to [any preceding] Claim 1.

a⁵ 11. (Amended) A method according to Claim 9 [or Claim 10] wherein the dosage is directed at a particular site in the eye.

a⁶ 13. (Amended) A method according to Claim 12 wherein the mean diameter of the jet and/or droplets is in the range 100 μm to 800 μm [, preferably 200 μm to 400 μm].

a⁷ 14. (Amended) A method according to claim 12 [or 13] wherein the total volume of treatment liquid in the dosage form does not exceed 10 μl .

Please add new Claims 16-20.

a⁷ 16. A dosage form according to Claim 3 wherein the jet or each droplet has a diameter in the range 100 to 800 μm .
Sixty

a⁷ contd

17. A dosage form according to Claim 3 wherein the jet or each droplet has a diameter in the range 200 to 400 μm .

18. A dosage form according to Claim 17 in which the total volume of treatment fluid does not exceed 10 μl .

19. A method of ophthalmic treatment comprising delivering to an eye a dosage form according to Claim 8.

20. A method according to Claim 12 wherein the mean diameter of the jet and/or droplets is in the range of 200 μm to 400 μm .

REMARKS

The claims have been amended to remove multiple-dependencies. New claims 16-20 have been added. These new claims find express support in the original claims. Thus, no new matter is added by this amendment.

Applicants respectfully solicit allowance of the claims as amended and passage of the case to issue. Should the examiner believe that a discussion of this matter would be helpful, he is invited to telephone the undersigned at (312) 913-0001.